CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Proflavine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02206048
NCT02206048N/ACompleted
CompareCT.gov

Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix

M.D. Anderson Cancer Center·interventional·Posted Aug 1, 2014·Updated Jul 25, 2022

In Brief

A clinical study evaluating Proflavine and High-Resolution Microendoscopy (HRME) Imaging for Cervix Carcinoma. Completed, enrolled 9 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if it is possible to get high-resolution microendoscopy (HRME) images of AIS tissue and/or tissue from microinvasive carcinoma right before a biopsy of the cervix. Researchers also want to learn if HRME images can show the difference between cancerous tissue and normal cervical tissue.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervix Carcinoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 1, 2014
Enrollment StartOct 2, 2015
Primary CompletionApr 21, 2021
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 11.9 years ago

Interventions

Proflavinedrug

0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.

High-Resolution Microendoscopy (HRME) Imagingprocedure

in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.